
Results 1 - 20 of 575 in Novartis
EU raids pharmaceutical companies for anticompetitive business deals
... Laboratories Ltd, India's biggest drug maker, Sanofi-Aventis SA, Teva Pharmaceutical Industries and a unit of Novartis AG as part of a widened probe of settlements between drug makers and brand-name pharmaceutical companies. (See: EU official raid ... Comment?
... desired price or lower by your option's expiration, or to be paid income if not. If you think, for example, that Novartis (NYSE: NVS ) is a good business at a good price, then writing puts on the stock is a sensible strategy, one that will could pay ... Comment?
Welcome to Club Biogeneric, Pfizer
... the club of drugmakers developing generic versions of biologic drugs, according to Bloomberg. (Nasdaq: TEVA ) , Novartis (NYSE: NVS ) , Hospira , and a few others have already gained approval in Europe for copycat versions of drugs such as Amgen 's ... Comment?
Wednesday's biggest gaining and declining stocks
Among the companies whose shares are expected to see active trade in Wednesday's session are Apple, Men's Wearhouse, Novartis, PepsiCo, Powell, Sara Lee, and TI. Comment?
Novartis AG Talks Up Promising Cancer Portfolio
Novartis AG expects to file for two new approvals of cancer drugs, including big hope Tasigna, by the end of the month and has several more on the way to further boost its lucrative portfolio. Comment?
Novartis highlights cancer drugs at R&D day
Swiss drugmaker Novartis on Wednesday said it's looking to build out its portfolio with 16 new compounds, with a particular focus on cancer drugs. Comment?
ASA404 to feature in Novartis Oncology Pipeline Update and at San Antonio Breast Cancer Symposium
LONDON and CAMBRIDGE, MA and BASEL, SWITZERLAND-- - Antisoma plc announces that Novartis, its partner for ASA404, will feature ASA404 in today's Oncology pipeline update for investors. Comment?
Mike Peed: Bark Hot Dogs, in North Park Slope.
... GRAPH: HONORE BROWN James Surowiecki speaks with Dan Vasella, the chairman and C.E.O. of the pharmaceutical company Novartis AG. MOCA , in L.A. MOMA . Comment?
Europeans Inspect Fewer Than 19 Chinese Drug Factories a Year
... 19 times in 2008, even though Western drug companies such as Pfizer (PFE), AstraZeneca (AZN), Eli Lilly (LLY) and Novartis (NVS) have hundreds of sites in China. (Source: EMEA. Click To enlarge.) BNET reported last week that the U.S. FDA has just ... Comment?
... in 2000 for $521-million, and Cobequid Life Sciences Inc., which was bought in that same year for $21-million by Novartis AG. Mr. Rankin was cleared of more serious insider-trading charges. However, he appealed his tipping conviction. "With the ... Comment?
Novartis's Tasigna Beats Gleevec in Leukemia Study; May Be `Blockbuster'
Novartis AG a s Tasigna, which ranks outside the Swiss drugmakera s top 20 products after two years on the market, may turn into a $1 billion seller after tests showed it was better at treating newly diagnosed leukemia than Gleevec. Comment?
Ariad, Cephalon Make ASH Splash: BioBuzz
... acute lymphoblastic leukemia (Ph+ CLL.) These are hard-to-treat patients because current leukemia drugs, including Novartis' ( NVS Quote ) Gleevec and Tasigna and Bristol-Myers Squibb's ( BMY Quote ) Sprycel, have limited or no positive effect. ... Comment?
Better Drug Stock: Pfizer or Merck?
... Each of these five rankings need more context -- like, how these companies stack up against key competitors such as Novartis (NYSE: NVS ) and Bristol-Myers Squibb (NYSE: BMY ) . But these basic numbers suggest that Merck is a better buy. What do you ... Comment?
U.S. FDA Panel Backs Novartis AG Transplant Drug
A U.S. advisory panel recommended approval of a Novartis AG drug to prevent rejection of transplanted kidneys, a Food and Drug Administration spokeswoman said on Monday. Comment?
Skepticism on Swine Flu's Danger Limits Europe's Pandemic Vaccine Demand
... against the pandemic virus by early next year. Public concerns that the vaccines made by GlaxoSmithKline Plc , Novartis AG and Baxter International Inc. may cause serious side effects have kept some Europeans on the sidelines since governments began ... Comment?
... loved." I was messing with small biotechs. Names you'd never hear until one Monday morning they were snapped up by Novartis (NYSE: NVS ) or Bristol-Meyers Squibb (NYSE: BMY ) . And tiny exploration and production outfits that summarily popped on ... Comment?
James Surowiecki speaks with Dan Vasella, the chairman and C.E.O. of the pharmaceutical company Novartis AG, about the current state of the industry, the company's shift away from the traditional model of profitability, and the growing influence of countries such as China, where Novartis plans to open a billion-dollar facility. Comment?
Table of Contents: December 14, 2009 : The New Yorker
w/Photo
... of Lydia Davis." James Surowiecki speaks with Dan Vasella, the chairman and C.E.O. of the pharmaceutical company Novartis AG. Browse the complete archive using the cover gallery. DVD of the Week : Richard Brody on "Women of the Night." Red Red Wine ... Comment?
MDB Capital i-banker lands at Idera Pharma
... pivotal time for Idera. The Massachusetts biotech announced recently that it was terminating a key partnership with Novartis AG (NYSE:NVS). The companies had for four years collaborated on the respiratory disease compound IMO-2134, with Novartis ... Comment?
InCyte's Experimental Pre-Leukemia Drug Curbed Symptoms, Research Finds
... patients with a disorder linked to acute leukemia, a study found. The drug, licensed last month by Swiss drugmaker Novartis A.G. , shrank spleen size, limited fatigue and improved walking ability in the research, reported today at the American ... Comment?